Sector Fund

Details as on June 30, 2019

Type of Scheme

An open ended equity scheme investing in pharma sector

Current Investment Philosophy

The Fund seeks to invest in pharma sector with focus on important segments of the sector viz Domestic Business, International & CRAMS and include deep value as well as high growth pharma businesses. The fund invests across market capitalization within the sector. It may suit investment horizon of around 2-3 years.

Date of Allotment

June 5, 2004

Fund Manager

Sailesh Raj Bhan

Benchmark

S&P BSE Healthcare TRI

Fund size

Monthly Average: ₹ 2,423.00 Cr Month End: ₹ 2,420.27 Cr

NAV as on June 28, 2019

Growth Plan	₹	141.8773	Direct - Growth Plan	₹	149.6829
Dividend Plan	₹	48.7867	Direct - Dividend Plan	₹	60.3939
Bonus Option	₹	141.8773	Direct - Bonus Option	₹	149.6829

Portfolio Turnover (Times) 0.34

Total Expense Ratio^

Regular/Other than Direct 2.05 Direct 1.36

Load structure Entry Load: Nil

Exit Load: 1% if redeemed or switched out on or before completion of 1 year from the date of allotment of units. Nil, thereafter.

Special Feature: Reliance Any Time Money Card

Please refer page no. 80 for explanation on symbol: ^ and @ wherever available

Portfolio as on June 30, 2019

Company/Issuer	% of Assets
Healthcare Services	
Fortis Healthcare Limited*	6.13
Thyrocare Technologies Limited	4.12
Narayana Hrudayalaya Limited	1.50
Pharmaceuticals	
Sun Pharmaceutical Industries Limited*	11.10
Divi's Laboratories Limited*	10.56
Cipla Limited*	9.83
Aurobindo Pharma Limited*	8.29
Lupin Limited*	7.17
Syngene International Limited*	6.94

Company/Issuer	% of Assets
Abbott India Limited*	6.52
Dr. Reddy's Laboratories Limited*	6.32
Sanofi India Limited*	6.10
Biocon Limited	5.60
Alkem Laboratories Limited	4.65
Cadila Healthcare Limited	2.52
FDC Limited	1.07
Equity Less Than 1 % of Corpus	1.35
Cash and Other Receivables	0.22
Grand Total	100.00

*Top 10 Holdings

For SIP performance refer page 59. For scheme performance refer page 61-68. For Fund manager wise scheme performance refer page 69-72.

Volatility Measures				
Standard Deviation 4.29	Beta	0.79	Sharpe Ratio	-0.06

Note: The above measures have been calculated using monthly rolling returns for 36 months period with 5.97% risk free return (FBIL Overnight MIBOR as on 28/06/2019).

Dividend History							
Record Date	Rate (₹/ Unit)	Cum Dividend NAV	Ex-Dividend NAV	Record Date	Rate (₹/ Unit)	Cum Divi dend NAV	Ex-Dividend NAV
Dividend Plan				Direct - Dividen	d Plan		
01-Mar-19	4.43	56.5884	51.5884	01-Mar-19	4.43	68.7031	63.7031
01-Mar-18	6.00	58.6103	52.6103	01-Mar-18	6.00	69.2904	63.2904
03-Mar-17	6.50	63.6381	57.1381	03-Mar-17	6.50	73.3984	66.8984


Past performance may or may not be sustained in future. Pursuant to dividend payment, NAV falls to the extent of payout & statutory levy (if applicable). Face Value-₹10.

Product Label

This product is suitable for investors who are seeking*:

- · Long term capital growth
- Investment in equity and equity related securities of pharma & other associated companies

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.



Investors understand that their principal will be at High risk